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Abstract
Background: In order to ascertain the impact of a biomarker-based (personalized) strategy, we compared outcomes between 
US Food and Drug Administration (FDA)–approved cancer treatments that were studied with and without such a selection 
rationale.
Methods: Anticancer agents newly approved (September 1998 to June 2013) were identified at the Drugs@FDA website. 
Efficacy, treatment-related mortality, and hazard ratios (HRs) for time-to-event endpoints were analyzed and compared in 
registration trials for these agents. All statistical tests were two-sided.
Results: Fifty-eight drugs were included (leading to 57 randomized [32% personalized] and 55 nonrandomized trials [47% 
personalized], n = 38 104 patients). Trials adopting a personalized strategy more often included targeted (100% vs 65%, 
P < .001), oral (68% vs 35%, P = .001), and single agents (89% vs 71%, P = .04) and more frequently permitted crossover to 
experimental treatment (67% vs 28%, P = .009). In randomized registration trials (using a random-effects meta-analysis), 
personalized therapy arms were associated with higher relative response rate ratios (RRRs, compared with their 
corresponding control arms) (RRRs = 3.82, 95% confidence interval [CI] = 2.51 to 5.82, vs RRRs = 2.08, 95% CI = 1.76 to 2.47, 
adjusted P = .03), longer PFS (hazard ratio [HR] = 0.41, 95% CI = 0.33 to 0.51, vs HR = 0.59, 95% CI = 0.53 to 0.65, adjusted 
P < .001) and a non-statistically significantly longer OS (HR = 0.71, 95% CI = 0.61 to 0.83, vs HR = 0.81, 95% CI = 0.77 to 
0.85, adjusted P = .07) compared with nonpersonalized trials. Analysis of experimental arms in all 112 registration trials 
(randomized and nonrandomized) demonstrated that personalized therapy was associated with higher response rate 
(48%, 95% CI = 42% to 55%, vs 23%, 95% CI = 20% to 27%, P < .001) and longer PFS (median = 8.3, interquartile range [IQR] = 5 
vs 5.5 months, IQR = 5, adjusted P = .002) and OS (median = 19.3, IQR = 17 vs 13.5 months, IQR = 8, Adjusted P = .04). 
A personalized strategy was an independent predictor of better RR, PFS, and OS, as demonstrated by multilinear regression 
analysis. Treatment-related mortality rate was similar for personalized and nonpersonalized trials.
Conclusions: A biomarker-based approach was safe and associated with improved efficacy outcomes in FDA-approved 
anticancer agents.
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Recently, a deeper understanding of cancer biology has begun 
to change old paradigms in cancer treatment. Molecular abnor-
malities are being described as oncogenic or as markers that 
permit differentiation of normal elements from malignant ones, 
offering a unique opportunity for target-directed treatment. The 
US Food and Drug Administration (FDA) has recently granted 
marketing authorization for the first next-generation genomic 
sequencer (1), which, along with rapidly declining costs, is mov-
ing genomic diagnostic tests to practice.
In 2004, only 11 targeted anticancer agents had entered clini-
cal trials (2), while in 2013 seven new targeted agents received 
approval by the FDA for cancer treatment, adding to an exten-
sive list (3). Additionally, many new molecular targeted agents 
are in development. Strategies to better select patient popula-
tions for these new drugs in order to maximize their benefits are 
in development as well.
Historically, many drugs were approved without a biomarker 
for patient selection, including most cytotoxic chemotherapies 
and some targeted agents. Treatment selection based on bio-
markers reflecting biology-specific features that permit differ-
entiation of normal vs malignant cells have brought remarkable 
advances in oncology. Illustrative examples are imatinib for the 
treatment of Bcr-Abl–aberrant chronic myelogenous leukemia 
(4) and trastuzumab for HER-2 overexpressing breast cancer (5), 
which, according to the FDA, started the concept of personalized 
medicine in cancer (6). In some cancers, a subgroup of patients 
whose tumors do not present the biomarker may actually have 
worse outcomes when treated with targeted agents (7,8).
Despite these examples, the evidence supporting the benefit 
of a personalized (biomarker-based) approach to cancer treat-
ment is still a matter of debate, with a need for an overview 
of existing quality data (9). Therefore, we performed a compre-
hensive analysis of clinical trials that led to FDA drug approval 
between September 1998 and June 2013. Our analysis included 
meta-analysis, meta-regression, Wilcoxon test, and weighted 
least regression analysis applied as appropriate to the 57 ran-
domized trials and the 112 total trials (randomized and non-
randomized). We aimed to compare efficacy outcomes between 
approved treatments that employed a personalized therapy 
strategy (matching a molecularly targeted compound with indi-
viduals harboring the cognate target) vs those who did not.
Methods
Search Strategy
Anticancer agents newly approved between September 1998 
(which represents FDA approval of trastuzumab for metastatic 
breast cancer, starting an era of biomarker-driven therapies) 
and June 2013 were identified on the FDA website (10). Agents 
approved for the treatment of advanced solid and hemato-
logic malignancies were selected for analysis. Agents approved 
for pediatric cancer, supportive care, loco-regional treatment, 
hormonal therapies, vaccines, and agents whose basic com-
pound had already been approved before September 1998 were 
excluded from analysis. The original and most recent package 
inserts for each agent were reviewed to identify original and pos-
terior indications and clinical trials leading to agent approval. 
Reports of original trials were obtained through MEDLINE or 
the ASCO meetings website (11) (if the clinical trial was not yet 
published). Whenever appropriate, we followed the Preferred 
Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) statement (12).
For the purpose of our analysis, personalized therapy and 
biomarker-based strategy were used interchangeably and carried 
the same meaning as “matched targeted therapy.” If a targeted 
agent was used, but it was not matched to the patient popula-
tion, it was not considered personalized. We defined personal-
ized therapy when a treatment met one of the following criteria: 
1) Cognate biomarker was used to select patients for treat-
ment or; 2) No biomarker was used, but at least 50% of patients 
are known to harbor the cognate biomarker. Homogeneity of 
biomarkers is generally found only in rare tumor types that 
are often defined by their specific molecular characteristic. 
Examples include (but are not limited to) hairy cell leukemia 
(~100 percent have BRAF mutations) and chronic myeloge-
nous leukemia (~100% carry Bcr-Abl rearrangements) (13,14). 
In all common solid tumors, any one biomarker is found in 
only a small subset of patients. A  drug was considered per-
sonalized if the half maximal inhibitory concentration (IC50) 
impacted the target at low nM range (<100 nM) (for small mol-
ecule inhibitors) or if the target was the primary one recog-
nized by an antibody.
A list of biomarkers accepted for classification of personalized 
therapy in this study is available online (Supplementary Table 1, 
available online).
Study Selection and Data Extraction
To be included in the analysis, a trial referred from package 
insert must have evaluated a drug in an experimental arm, 
either as a single agent or a combination and reported efficacy 
endpoints. When the agent was approved in combination, the 
experimental drug was used for classification. We considered 
response rate (RR), progression-free survival (PFS) or time to 
tumor progression (TTP) when PFS was not available, and over-
all survival (OS) as acceptable efficacy endpoints. Further clini-
cal trials of the same drug were included in the analysis if a new 
indication for a different tumor type and/or a new combination 
and/or a new biomarker for patient selection were approved. In 
these cases, the trials leading to the change in the FDA indica-
tion were included as part of the data analysis. Data extrac-
tion was conducted independently by two investigators (DLFJ 
and MS) and any discrepancies were resolved by consensus in 
frequent meetings in the presence of the principal investigator 
(RK). All deaths reported by investigators as “possibly,” “prob-
ably,” or “definitely” related to treatment were considered tox-
icity-related deaths.
Responses were recorded according to the response cri-
teria adopted in the trial: for solid tumors, partial and com-
plete responses as per Response Evaluation in Solid Tumors 
Criteria (RECIST) (15) or World Health Organization Criteria 
(WHO) (16); for chronic myelogenous leukemia (CML), major 
cytogenetic responses; for multiple myeloma (MM), partial 
and complete responses; for acute myelogenous leukemia 
(AML), complete responses; and for lymphomas, partial and 
complete responses by WHO criteria. We considered as valid 
biomarkers results from mutational analysis, cytogenetic or 
fluorescence in situ hybridization (FISH) tests,or immunohis-
tochemistry assays (for anti-HER2 therapies or for hemato-
logical surface markers).
Statistical Analyses
All statistical analyses were performed/confirmed by statisti-
cians (CW and JJL). The primary outcome of this meta-analysis 
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was to compare efficacy outcomes (RR, PFS, and OS) and treat-
ment-related mortality between agents developed under a 
biomarker-based rational (personalized therapy) vs those that 
did not. For the subgroup of randomized trials in which an 
experimental arm was compared with a control, we performed 
a meta-analysis of hazards ratios (HRs) for PFS/TTP and OS and 
relative response rate ratio (RRR) for personalized trials vs non-
personalized using a random effects model. The random effects 
model takes into account of both within-study variation and 
between-study variation. Relative risk for response ratio was 
calculated as the response rate in the experimental arm divided 
by the response rate in the control arms. Randomized trials in 
which both arms were considered personalized were excluded 
from this analysis.
For the trials providing only the hazard ratios without 95% 
confidence intervals (CIs), we used the method by Tierney et al. 
(17) to estimate 95% confidence intervals when a P value for 
the hazard ratio was available. For the randomized trials with 
a 1:1 randomization ratio where the hazard ratio was not pro-
vided but the number of events and the number of randomized 
patients was available, we used the method of Tierney et al. (17) 
to estimate the HR and then used the method of Altman (18) 
to estimate the 95% confidence intervals for the hazard ratios 
when a P value for the difference between the experimental arm 
and the control arm was available.
A random effects model based on estimate (log of the 
response rate, log relative response rate ratios, log hazard 
ratios) and their standard error was used to pool the esti-
mate across studies using the DerSimonian-Laird method 
(19). Random effects meta-regression model (18,20) via linear 
mixed model was used to assess the relationship between 
the estimates and personalized therapy status, adjusted for 
other potential confounders/mediators. For the meta-regres-
sion models, we assessed these mediators as potential con-
founders: 1) Type of tumor: solid vs hematologic, 2) Previous 
treatment: yes vs no, 3) Control arm (placebo or BSC vs drug), 
4) Allowance of cross-over (for OS only). Heterogeneity between 
studies was quantified by the between-study variance tau2 and 
the Cochran’s Q test and/or the I2 statistics, which describes the 
percentage of variation across studies that is because of hetero-
geneity rather than chance (21). Studies were classified as pre-
senting low (I2 ≤ 50%), moderate (I2 > 50% and ≤ 75%), or high 
heterogeneity (I2 ≥75%).
Similarly, for randomized and nonrandomized trials com-
bined, we performed a pooled analysis of the response rates 
(RRs) for experimental arms using the random effects model 
and used the meta-regression model to adjust for media-
tors/confounders: 1) Type of tumor: solid vs hematologic, 
2) Study design: randomized vs nonrandomized, 3) Previous 
chemotherapy: yes vs no, 4) Number of patients evaluable for 
response in the experimental arm (>178 vs <178). For rand-
omized and nonrandomized trials (single-arm studies) we also 
compared a pooled analysis of median PFS and OS for experi-
mental arms. To account for differences between studies, we 
weighted the analysis in proportion to the study sample size 
using a weighted least-squares analysis. Statistical dispersion 
was measured by the interquartile range (IQR; the distance 
between the 75th and the 25th percentile). Assessment of 
independent samples was done using the Wilcoxon rank-sum 
test. Multiple linear regression models were fit to assess the 
association between PFS and OS and several independent vari-
ables, in which the variables included the study design (rand-
omized vs nonrandomized), enrichment for molecular targets 
(personalized vs not personalized), previous systemic thera-
pies (chemo naive vs pretreated), FDA approval date (before 
the median vs after; the median date was 10/01/2007), number 
of patients per arm (6–178; 179–839), type of treatment (chem-
otherapy vs targeted), administration route (oral vs injection), 
single agent vs combination, and tumor type (solid vs liquid). 
The final model for PFS analysis contained only the independ-
ent variables that were statistically significant in the univari-
ate analysis, while for OS analysis variables with P values of 
less than .2 were also included. A  P value of .05 or less was 
considered statistically significant. All statistical tests were 
two-sided.
Statistical analyses were done with R (http://www.r-project.
org/) using packages “meta” and “metaphor” and SPSS version 
22 (SPSS) software.
Results
Search Results
We identified 74 FDA-approved drugs for adult cancer treat-
ment indications. After applying previously described criteria, 
we included 58 approved drugs. Most of the drugs (n = 43, 74%) 
were classified as targeted agents and approved exclusively for 
treatment of solid tumors (n = 34, 59%). Review of the package 
insert from included drugs identified 57 randomized (18 [32%] 
personalized) and 55 nonrandomized trials (26 [47%] personal-
ized), which were the basis of our analysis. A diagram describ-
ing the inclusion of trials in the different analyses is available 
online (Supplementary Figure 1, available online). These trials 
enrolled a total of 38 104 patients (30 701, randomized; 7403, 
nonrandomized trials) (Supplementary Tables 2 and 3, avail-
able online).
Characteristics of Trials
Personalized trials accrued a median number of 152 patients 
(range  =  7–533) per experimental arm compared with 204.5 
(33–862) for nonpersonalized trials (P  =  .29). Agents that were 
tested with a personalized strategy were all considered to be 
targeted agents (Table 1). In contrast, only 65% were classified 
as targeted when a nonpersonalized approach was employed 
(P < .001). Statistically significant differences between person-
alized vs nonpersonalized trials were also detected regarding 
increased use of oral (68% vs 35%, P  =  .001) and single agents 
(89% vs 71%, P = .04), respectively. Allowance for crossover to the 
experimental arm was higher in randomized trials with person-
alized treatments in comparison with nonpersonalized (67% vs 
28%, P = .009). There was a suggestion for nonpersonalized trials 
to be more frequently randomized, although with no statistical 
significance (P = .12) (Table 1; Supplementary Table 4, available 
online).
Meta-Analysis of Relative Benefits of Personalized 
Therapy in Randomized Registration Trials
We performed a meta-analysis of relative benefits in RR, PFS, 
and OS between the experimental arms and their corresponding 
control arms for randomized registration trials (Table 2). Fifty-
one studies were included in the RRR and PFS analysis. The RRR 
analysis showed a higher likelihood of response with a person-
alized compared with nonpersonalized strategy (RRR = 3.82, 95% 
CI = 2.51 to 5.82, vs 2.08, 95% CI = 1.76 to 2.47, P = .009) (Figure 1A). 
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After adjusting for other mediators in the meta-regression 
model, personalized therapy remained as a statistically signifi-
cant predictor of RRR (adjusted P = .03) (Table 2).
In randomized trials, the estimated hazard ratio for PFS 
of experimental compared with control arms was 0.41 (95% 
CI  =  0.33 to 0.51) for personalized compared with 0.59 (95% 
CI  =  0.53 to 0.65) for nonpersonalized studies (nonadjusted 
P = .004), indicating a greater improvement in PFS in the person-
alized approach (Figure 1B), which was confirmed in the meta-
regression model (adjusted P < .001). In RRR and PFS analysis, 
heterogeneity between studies within personalized and nonper-
sonalized cohorts was classified as high (I2 > 75%).
For the 46 randomized trials where the hazard ratio of OS 
and corresponding 95% confidence interval were provided, the 
estimated hazard ratios for OS were 0.71 (95% CI = 0.61 to 0.83) 
for personalized compared with 0.81 (95% CI  =  0.77 to 0.85) 
for nonpersonalized studies. This difference was not statisti-
cally significant (Figure 1C). With adjustment for other media-
tors, including crossover to experimental arm and type of 
tumor (solid vs hematologic), personalized therapy was associ-
ated with slightly lower hazard ratios for OS (adjusted P = .07). 
Heterogeneity between studies within personalized and non-
personalized cohorts was classified as moderate (50% < I2 ≤ 75%).
An exploratory univariate analysis suggested, amongst 
biomarker-driven trials, response rate was improved for tri-
als adopting biomarkers such as immunohistochemistry or 
FISH vs mutation analysis, while for RRR the opposite was true 
(Supplementary Table 5, available online). The number of stud-
ies in these analyses is small and might be subject to bias, and 
this statistical significance did not hold in multivariate analysis 
(results not shown). In addition, no statistically significant differ-
ences were observed for PFS or OS in the same stratified analysis.
Personalized Therapy and Response Rate in All Trials
Of the 111 trials (both randomized and nonrandomized) report-
ing responses, the RR in the experimental arm was statistically 
significantly higher in the personalized trials compared with 
nonpersonalized trials (random effect model meta-analysis) 
(RR = 48%, 95% CI = 42% to 55%, vs RR = 23%, 95% CI = 20% to 
27%, respectively, P < .001), even within randomized and non-
randomized subgroups (Table 3). We also observed higher RRs in 
nonrandomized vs randomized studies (40% vs 25%, P < .001), 
treatment-naïve vs pretreated population (40% vs 29%, P = .01), 
trials with a smaller number of patients (38% vs 27%, P = .04), and 
hematologic vs solid tumors (46% vs 24%, P < .001). After adjust-
ments for statistically significant factors, personalized therapy 
remained a statistically significant determinant of response rate 
in experimental arms of registration trials, with an adjusted 
relative risk ratio of 2.22 (95% CI = 1.64 to 3.02) when compared 
with nonpersonalized arms (P < .001). In addition, trials involv-
ing hematologic tumors and a treatment-naïve population were 
also statistically significantly associated with higher RR in the 
meta-regression model.
Personalized Therapy and Progression-Free Survival
Of the 112 trials included in our analysis, 90 (80%) reported PFS as 
an efficacy outcome. The median PFS for the experimental arm of 
Table 1. Comparison of the main characteristics between personalized and nonpersonalized trials
Characteristic
Personalized 
trials (n = 44)
Non-personalized 
trials (n = 68) P*
Median number of patients per 
experimental arm (range)†
152 (7–553) 204.5 (33–862) .29
Trial design, No. (%)
 Randomized 18 (41) 39 (57) .12
 Nonrandomized 26 (59) 29 (43)
Class agent, No. (%)
 Cytotoxic 0 24 (35) <.001
 Targeted 44 (100) 44 (65)
Tumor type, No. (%)
 Solid 20 (45) 47 (69) .02
 Hematologic 24 (55) 21 (31)
Route, No. (%)
 Intravenous 14 (32) 44 (65) .001
 Oral 30 (68) 24 (35)
Treatment, No. (%)
 Single agent 39 (89) 48 (71) .04
 Combination 5 (11) 20 (29)
Population, No. (%)
 Treatment-naïve 13 (30) 18 (26) .83
 Previous treatment 31 (70) 50 (74)
Control arm (for randomized trials), No. (%)
 Active treatment 13/18 (72) 28/39 (72) 1.00
 Placebo/BSC 5/18 (28) 11/39 (28)
Crossover allowed (for randomized trials), No. (%)
 Yes 12/18 (67) 11/39 (28) .009
 No 6/18 (33) 28/39 (72)
* Wilcoxon rank-sum test (two-sided).
† Not including control arm for randomized trials. BSC = best supportive care.
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these trials was 6.2 months (interquartile range [IQR] = 5). For 13 
trials, the data were not available, and for nine the median PFS was 
“not reached” (all personalized). These trials were excluded from 
the analysis. Experimental arms that included a personalized ther-
apy had a median PFS of 8.3 months (IQR = 5) vs 5.5 months (IQR 
= 5) for nonpersonalized therapy (P < .001) (Table 4). In addition, 
treatment-naïve population was also a statistically significant fac-
tor associated with longer PFS in the univariate analysis (P = .004), 
but only the adoption of a personalized strategy for treatment 
selection in a trial was confirmed as an independent predictor of 
longer PFS in the multilinear regression analysis (P = .002).
Personalized Therapy and Overall Survival
Of the 112 trials, the median OS of the experimental arm was 
reported in 60 (54%). Median OS in these trials was 14.2 months 
(IQR = 9). For 22 trials, the data were not available, and for 30 
trials the median OS was not reached (23 of them were per-
sonalized). Trials employing a personalized therapy strategy 
described a statistically significant longer OS (19.3  months, 
IQR = 17) compared with nonpersonalized therapy (13.5 months, 
IQR = 8, P =  .01) (Table 4). In the multilinear regression model, 
personalized therapy remained as the only factor selected as an 
independent predictor of survival (P = .04).
Eighty-one trials (72%) had information about treatment-
related deaths. Treatment-related mortality was 1.6 percent 
(95% CI = 1% to 2.4%) for personalized vs 1.4 percent (95% CI = 1% 
to 2%) for nonpersonalized trials, which was not statistically dif-
ferent (P = .74).
Discussion
Our comprehensive review of trials leading to FDA approval of 
oncology drugs included a meta-analysis, in which the adoption 
of a biomarker-based (personalized) approach was an independ-
ent factor associated with a higher RRR (P = .03) and prolongation 
of PFS (P < .001), and a suggestion towards longer OS, although 
not statistically significant (P  =  .07) compared with a nonper-
sonalized therapy strategy in randomized trials. Our results 
demonstrated a relative increase in median PFS for the use of 
personalized vs nonpersonalized agents against their respec-
tive control arms in randomized trials and a relative increase 
in median OS. In addition, a systematic review of all registration 
trials (both randomized and nonrandomized) confirmed that 
personalized therapy was statistically significantly and inde-
pendently associated with higher RR (P < .001) and longer PFS 
(P = .002) and OS (P = .04), even after adjustments for confound-
ing variables.
Personalized therapy trials also had treatment-related 
mortality rates similar to nonpersonalized trials. The toxicity-
mortality rate described herein is similar to that in a previous 
report of phase I trials that evaluated anticancer drugs studied 
by the National Cancer Institute (mortality that was possibly 
drug related = 0.49%) (22,23). Other studies have also shown that 
safety and dose in early trials is highly predictive for later trials, 
possibly accounting in part for the low drug-related death rates 
in our registration trials (24).
In our study, registration trials for FDA approval of new anti-
cancer agents included 57 randomized and 55 nonrandomized 
trials (38 104 patients). A  meta-analysis of hazard ratios for 
Table 2. Meta-analysis (univariate and multivariate) using random effects model according to trial characteristics (including personalized vs 
non-personalized drugs) in randomized registration trials
Characteristic
Relative response rate ratio PFS OS
N RRR (95% CI) N HR (95% CI) N HR (95% CI)
Personalized status
 Personalized 14 3.82 (2.51 to 5.82) 13 0.41 (0.33 to 0.51) 13 0.71 (0.61 to 0.83)
 Non-personalized 37 2.08 (1.76 to 2.47) 38 0.59 (0.53 to 0.65) 33 0.81 (0.77 to 0.85)
 P (univariate) .009 .004 .11
 P (meta-regression)*,† .03 <.001 .07
Control arm
 Placebo 16 7.03 (4.27 to 11.58) 15 0.42 (0.37 to 0.48) 15 0.81 (0.74 to 0.90)
 Active treatment 35 2.08 (1.75 to 2.47) 36 0.60 (0.54 to 0.67) 31 0.78 (0.74 to 0.83)
 P (univariate) † <.001 <.001 .51
 P (meta-regression) *,† <.001 <.001 NA
Tumor type
 Solid 43 2.27 (1.92 to 2.69) 44 0.56 (0.50 to 0.62) 41 0.81 (0.77 to 0.85)
 Hematologic 8 3.30 (1.93 to 5.63) 7 0.42 (0.33 to 0.54) 5 0.60 (0.49 to 0.73)
 P (univariate) † .2 .04 .004
 P (meta-regression) *,† NA .004 .006
Treatment status
 Naïve 22 2.23 (1.76 to 2.83) 23 0.54 (0.46 to 0.63) 20 0.77 (0.71 to 0.84)
 Pretreated 29 2.70 (2.09 to 3.50) 28 0.54 (0.47 to 0.61) 26 0.81 (0.76 to 0.87)
 P (univariate) † .29 .99 .37
Cross-over allowed
 Yes 23 3.67 (2.86 to 4.69) 22 0.42 (0.37 to 0.47) 21 0.76 (0.68 to 0.85)
 No 28 1.68 (1.45 to 1.95) 29 0.65 (0.58 to 0.72) 25 0.80 (0.76 to 0.84)
 P (univariate) † <.001 <.001 .48
 P (meta-regression)*,† NA NA .32
* Meta-regression analysis was performed including only factors considered statistically significant in univariate analysis. In the case of allowance for crossover 
for RRR and PFS analysis, meta-regression was not performed because crossover occurred after progression and could therefore not confound responses or PFS. 
HR = hazard ratio; N = number of trials included; NA = not applicable; OS = overall survival; PFS = progression-free survival; RRR = relative response rate ratio.
† P values were two-sided.
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Figure 1. Forest-plot representing the relative response rate ratio (A), hazard ratios for progression-free survival (PFS) (B), and overall survival (OS) (C) between experi-
mental and control arms by personalized therapy status in randomized registration trials. Studies are labeled by first author’s last name, and references were numbered 
according to supplementary references. In (A), RRR is shown and lines to the right of the vertical line indicate improvement in the experimental arm. In (B and C), the 
plots show hazard ratios (HRs) and, therefore, lines to the left of the vertical line indicate improvement (ie, lower HR for PFS or OS) for the experimental arm. P values 
were tested for subgroup differences (chi-square) and are two-sided. df = degree of freedom; Q = Cochran’s Q test.
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time-to-event endpoints using the random-effects model is the 
most acceptable statistical approach to compare the efficacy of 
two different strategies amongst heterogeneous trials. However, 
this type of analysis was not possible (for PFS and OS) in most of 
our nonrandomized trials because the confidence intervals or 
the variances for the medians were not reported. Therefore, the 
meta-analysis was applied to the randomized studies for the 
hazard ratios for PFS/OS and RRR and to all studies for response 
rates (because the latter data were fully available in both rand-
omized and nonrandomized studies). Importantly, in our group 
of studies personalized trials were more often nonrandomized 
(59% vs 43% for nonpersonalized), although not statistically sig-
nificant (P = .12). Because the decision to not randomize a trial 
is often based on having observed high response rates in earlier 
clinical trials, the trend to nonrandomization, and hence exclu-
sion of a higher number of trials in the personalized group, 
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could have attenuated the effects observed in the meta-anal-
ysis (25).
In order to include both randomized and nonrandomized 
studies in PFS/OS analysis, we performed a weighted data analy-
sis of the 112 registration trials. Although using median survival 
times at a particular point in time (rather than hazard ratios 
between experimental and control arms) has intrinsic limita-
tions (26), the advantage of this approach was that substan-
tially more trials were included, as we were no longer limited 
to randomized trials. However, inclusion of the nonrandomized 
trials may lead to unrecognized bias arising from different 
populations being compared without the reference of a control 
group. In addition, the weighted analysis can also introduce a 
bias, because some authors have shown that personalized tri-
als tend to be smaller (27), perhaps because the hypothesized 
response rates are higher and some molecular subtypes of can-
cers are rare. We also observed a smaller number of patients on 
experimental arms of personalized trials vs nonpersonalized 
(median = 152 vs 204 patients), though this difference was not 
statistically significant (P = .29). Finally, there was a statistically 
significantly higher number of studies not reaching a median 
PFS/OS within the personalized category (P < .001). Because 
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no median was available, we excluded these studies, though 
these trials might be expected to have the longest PFS/OS. This 
approach might have biased the analysis against personalized 
trials. Despite these factors, our results revealed better outcomes 
with a personalized strategy. All personalized drugs were classi-
fied as targeted agents, and no cytotoxic agents were considered 
personalized. This finding may reflect the fact that the precise 
mechanism of action of cytotoxic agents and the biomarkers for 
them have only recently been explored (28,29).
The hazard ratio for overall survival in the randomized trials 
was better with personalized treatment, although this did not 
reach statistical significance in multivariate analysis (P = 0.07). 
A  possible explanation for this finding was a statistically sig-
nificantly higher crossover to the experimental arm in per-
sonalized trials. In addition, the small number of randomized 
trials (evaluable = 46 in total with 13 being personalized) may 
have precluded definitive associations with survival. Successful 
drugs developed with a strong biologic rationale, including a 
biomarker for treatment selection, often demonstrate higher 
antitumor activity in early trials (30,31). This is a plausible rea-
son for the majority of personalized trials allowing crossover 
to the experimental arm, confounding the assessment of OS 
(32–35). When both randomized and nonrandomized trials were 
included in the survival multilinear regression analysis, person-
alized therapy was the only independent factor associated with 
longer OS. It is conceivable that a personalized approach might 
show even greater impact earlier in the disease course (36).
Our study is not the first to demonstrate the benefit of a 
personalized treatment approach. Von Hoff et  al. (37) showed 
that treatment matched to profiled tumors rendered a statisti-
cally significantly longer PFS when compared with the patient’s 
previous PFS on a nonselected treatment. Other studies with a 
similar design (using patients as their own controls) suggested 
that a personalized approach was feasible and more effective 
than using a nonselected treatment (38–40) Indeed, in mela-
noma, the median PFS on personalized phase I  therapy was 
longer than the PFS for these patients on their prior first-line 
standard treatment (39). Many of these studies were conducted 
when few biomarkers for treatment selection were available or 
validated; thus, it might be expected that salutary effects would 
increase as more potent “omics” diagnostic technology becomes 
available.
Previous evidence to support a personalized treatment 
approach was also shown by intertrial comparisons. Janku 
et  al. analyzed phase II trials in non–small cell lung cancer 
and demonstrated that treatment arms enriched for patients 
with molecular targets had a higher median RR (48.8% vs 9.7%, 
P = .005) and longer median PFS (6 vs 2.8 months, P = .005) and OS 
(11.3 vs 7.5 months, P = .05) as compared with those of patients 
not selected with a biomarker-driven rational (41). In multivari-
ate analysis, only studies enriched for patients with molecular 
targets or including drugs that eventually gained FDA approval 
were associated with better outcomes. A substantial prolonga-
tion of PFS and OS was also previously reported for some FDA-
approved agents in a range of different solid tumors when a 
targeted population was selected by a biomarker (27).
Our study has some limitations. First, we only included suc-
cessful FDA-approved agents. Certainly, some cancer drugs, bio-
markers, and/or personalized or nonpersonalized approaches 
were tested and failed during drug development (42), possibly 
affecting the generalizability of our findings. Second, our study 
did not restrict itself to a tumor type or a single biomarker. There 
was a wide variation in the nature and number of tests selected 
for each personalized therapy, and not all biomarkers were 
Table 3. Meta-analysis (univariate and multivariate) using random 
effects model comparing the response rate in the experimental arms 
between personalized and nonpersonalized registration trials. Un-
like Table 2, data from both randomized and nonrandomized trials 
were included
Characteristic
Response rate in the  
experimental arm
No. of studies RR % (95% CI)
Personalized status
 Personalized 44 48 (42 to 55)
 Nonpersonalized 67 23 (20 to 27)
 P (univariate) <.001
 P (meta-regression)* <.001
Study design†
 Randomized 56 25 (21 to 31)
 Nonrandomized 55 40 (35 to 45)
 P (univariate) <.001
 P (meta-regression)* .14
Tumor type
 Solid 66 24 (20 to 28)
 Hematologic 45 46 (40 to 53)
 P (univariate) <.001
 P (meta-regression)* <.001
Treatment status
 Naïve 30 40 (33 to 49)
 Pretreated 81 29 (25 to 34)
 P (univariate) .01
 P (meta-regression)* <.001
Class of agent
 Cytotoxic 23 30 (24 to 36)
 Targeted 88 33 (28 to 38)
 P (univariate) .44
 P (meta-regression)* NA
Single agent
 Yes 87 31(27 to 36)
 No 24 35 (28 to 43)
 P (univariate) .39
 P (meta-regression)* NA
Patients per arm‡
 6–178 56 38 (33 to 44)
 179–839 55 27 (22 to 32)
 P (univariate) .04
 P (meta-regression)* .19
Route
 Oral 53 26 (23 to 35)
 Intravenous 58 36 (31 to 41)
 P (univariate) .09
 P (meta-regression)* NA
Approval date‡
 09/1998-09/2007 53 35 (29 to 42)
 10/2007-06/2013 58 30 (25 to 35)
 P (univariate) .23
 P (meta-regression)* NA
* Meta-regression analysis was performed, including only factors considered 
statistically significant in univariate analysis; otherwise, analysis was not 
applicable for the characteristic. All P values were two-sided. CI = confidence 
interval; RR = rate ratio.
† Response rates (95% CI) in the experimental arm were 41% (30%-
52%) for randomized personalized trials (n = 18 studies), 20% (15%-
25%) for randomized nonpersonalized trials (n = 38), 54% (46%-61%) 
for nonrandomized personalized trials (n = 26), and 29% (26%-34%) for 
nonrandomized nonpersonalized trials (n = 29); all P values were less 
than .001 for comparison of personalized vs nonpersonalized trials within 
randomized and nonrandomized trials.
‡ Cutoff used was the median of distribution.
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associated with a validated approved companion diagnosis. It is 
possible that the personalized strategy has differential benefits 
depending on histology or biological context. However, the fact 
that we analyzed all registration trials in the time period also 
supports the validity of the observations across cancer types and 
genomic biomarkers. Another limitation was our inclusion of an 
analysis of nonrandomized trials in addition to our analysis of 
randomized trials. Both analyses produced consistent results, 
but nonrandomized trials may lead to unidentifiable bias aris-
ing from different patient populations being compared. Because 
many personalized trials were nonrandomized, it was neverthe-
less felt to be important to include this additional analysis of 
all studies. Finally, all included personalized therapies were tar-
geted agents, so we cannot extend our findings to personaliza-
tion of hormonal agents, cytotoxic drugs, or immunotherapies.
Our data indicate that personalized therapy, defined as 
biomarker-based targeted treatment in the context of drugs 
that reached FDA approval, is associated with increased clini-
cal benefit across tumor types and markers, as demonstrated 
by substantially higher response rates, longer time to disease 
progression, and longer survival, as well as improved relative 
response rates and hazard ratios for PFS in randomized trials, 
with no compromise in treatment-related mortality.
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Table 4. Survival outcomes of patients on randomized and nonrandomized registration trials of anticancer agents from 09/1998 to 06/2013
Characteristics
Progression-free survival Overall survival
Studies, 
No. Patients, N
Median, 
mo (IQR) P* Multilinear†
Studies, 
No. Patients, N
Median, 
mo (IQR) P* Multilinear†
Total studies 90 18 455 6.2 (5) 60 13 865 14.2 (9)
Personalized
 Yes 28 4137 8.3 (5) <.001 0.002 11 1842 19.3 (17) .01 0.04
 No 62 14 318 5.5 (5) Coeff:  
3.52 SE:1.08
49 12 023 13.5 (8) SE: 3.21  
Coeff: 6.72
Study design
 Randomized 54 14 936 6.7 (6) .17 37 11 294 14.4 (9) .16 0.56
 Nonrandomized 36 3519 5.65 (5) 23 2571 13.7 (10) SE: 2.87  
Coeff: 1.69
Treatment status
 Naïve 27 6765 7.4 (5) .004 0.07 20 5460 15.3 (13) .11 0.39
 Pretreated 63 11 690 5.6 (5) SE: 0.93  
Coeff: 1.72
40 8405 14 (8) SE: 2.30  
Coeff: 2.01
Approval date‡
 09/1998-09/2007 44 7558 6.4 (5) .84 30 6142 14.5 (11) .91
 10/2007-06/2013 46 10 897 6 (5) 30 7723 13.7 (9)
Patients per arm‡
 6–178 44 4000 6.7 (5) .61 25 2300 14.5 (13) .96
 179–839 46 14 455 6.2 (4) 35 11 565 13.8 (8)
Agent
 Cytotoxic 22 5100 5.6 (3) .11 18 4371 13.4 (5) .14 0.20
 Targeted 68 13 355 6.7 (5) 42 9494 15.7 (12) SE: 2.53  
Coeff: 3.27
Route
 Oral 38 8030 6.8 (6) .11 22 5276 16.5 (11) .19 0.79
 Intravenous 52 10 425 5.8 (5) 38 8589 13.6 (6) SE: 2.38 
Coeff: 0.62
Single agent
 Yes 65 10 939 5.7 (5) .13 40 7852 14 (9) .25
 No 25 7486 6.9 (5) 20 6013 14.2 (11)
Tumor type
 Solid 64 15 618 6.2 (5) .39 46 12 117 13.5 (10) .51
 Hematologic 26 2837 6.9 (5) 14 1748 15.7 (8)
* Wilcoxon rank-sum test (univariate analysis). All P values were two-sided. Coeff = coefficients; FDA = US Food and Drug Administration; IQR = interquartile range; 
SE = standard error.
† For progression-free survival analysis, multilinear regression analysis included only factors considered statistically significant on univariate analysis, while for OS 
factors with P values of less than .2 were included in the model.
‡ Cutoff used was the median of distribution.
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